China
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
IP firm leaders share why they remain positive in the face of falling patent applications from US filers, and how they are meeting a rising demand from China
The Via members, represented by Licks Attorneys, target the Chinese company and three local outfits, adding to Brazil’s emergence as a key SEP litigation venue
Despite a broader slowdown in US IP partner hiring in 2025, litigation demand drove aggressive lateral expansion at select firms
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyXiaohui Wu of Wanhuida Intellectual Property reports on a ruling by the Supreme People’s Court of China that emphasises that the determination of common knowledge in the assessment of inventiveness should be incontrovertible -
Sponsored by Liu, Shen & AssociatesAn increasing number of foreign companies are conducting research and development in China. Xuelan Yue of Liu Shen & Associates considers the implications and how to incentivise inventors
-
Sponsored by Liu, Shen & AssociatesDanchen Cheng of Liu Shen & Associates discusses the consequences of China’s amended patent law for partial design patent applications
-
Sponsored by Purplevine IPXiaoyan Zhou of Purplevine IP analyses the Fifth Set of Listing Standards for Medical Device Companies on STAR Market of the Shanghai Stock Exchange, which encourages companies to develop core technologies
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
-
Sponsored by Purplevine IPXiaoyan Zhou of Purplevine IP explains how the introduction of administrative measures for registering, and filing records relating to, medical devices in China should affect companies’ IP strategy
